clinical trial · NCT06788639
A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company·—·recruiting·n = 300
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Lisocabtagene maraleucel
brief summary
The purpose of this study is to characterize the long-term safety of lisocabtagene maraleucel (liso-cel), focusing on patients treated in the chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities
started
Feb 4, 2025
primary completion
Jun 30, 2044
completion
Jun 30, 2044
last updated
Feb 24, 2025
official title
Non-interventional Cohort Study of Patients Treated With Liso-cel (Lisocabtagene Maraleucel) for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Post-Marketing Setting
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol